|  | Total | Viral load >= 400 copies/ ml N (%) | Unadjusted Odds ratio | 95% confidence interval | P value* | Adjusted Odds ratio | 95% confidence interval | P value* |
---|---|---|---|---|---|---|---|---|---|
Sex | Male | 914 | 258 (28) | 1 | - | 0.31 | 1 | Â | 0.52 |
 | Female | 39 | 14 (36) | 1.42 | 0.73–2.78 |  | 1.38 | 0.53–3.61 |  |
Age – grouped (years) | <35 | 225 | 53 (24) | 1 |  | 0.16 | 1 |  | 0.33 |
 | 35–39 | 199 | 51 (26) | 1.12 | 0.72–1.74 |  | 1.50 | 0.83–2.71 |  |
 | 40–44 | 227 | 70 (31) | 1.45 | 0.95–2.20 | Pt = 0.01 | 1.43 | 0.82–2.52 |  |
 | 45–49 | 166 | 53 (32) | 1.52 | 0.97–2.38 |  | 1.89 | 1.04–3.43 |  |
 | >= 50 | 136 | 45 (33) | 1.60 | 1.00–2.57 |  | 1.50 | 0.77–2.93 |  |
Site | Site A | 165 | 35 (21) | 1 | - | <0.001 | 1 | Â | <0.001 |
 | Site B | 238 | 44 (18) | 0.84 | 0.51–1.38 |  | 0.71 | 0.39–1.32 |  |
 | Site C | 198 | 78 (39) | 2.41 | 1.59–3.86 |  | 2.38 | 1.32–4.31 |  |
 | Site D | 145 | 49 (34) | 1.90 | 1.14–3.15 |  | 1.80 | 0.92–3.50 |  |
 | Site E | 207 | 66 (32) | 1.74 | 1.08–2.79 |  | 1.70 | 0.88–3.31 |  |
WHO stage** (n = 55 missing) | 1–2 | 242 | 52 (21) | 1 | - | 0.02 | 1 |  | 0.007 |
 | 3 | 415 | 131 (32) | 1.69 | 1.16–2.44 |  | 2.08 | 1.28–3.34 |  |
 | 4 | 241 | 66 (27) | 1.38 | 0.91–2.09 |  | 2.03 | 1.14–3.62 |  |
CD4 count at baseline (× 106/l) (n = 45 Missing) | <= 50 | 126 | 37 (29) | 1 | - | 0.5 |  |  |  |
 | 51–100 | 136 | 46 (34) | 1.23 | 0.73–2.07 |  |  |  |  |
 | 101–200 | 332 | 95 (29) | 0.96 | 0.61–1.51 |  |  |  |  |
 | 201–350 | 273 | 70 (26) | 0.83 | 0.52–1.33 |  |  |  |  |
 | > 350 | 41 | 13 (32) | 1.12 | 0.52–2.39 |  |  |  |  |
Viral load at baseline (copies/ml) (n = 61 missing) | <= 10,000 | 179 | 36 (20) | 1 | Â | 0.02 | 1 | Â | <0.001 |
 | 10,001– | 443 | 134 (30) | 1.72 | 1.13–2.62 |  | 3.63 | 1.88–7.00 |  |
 | 100,000 | 270 | 85 (31) | 1.83 | 1.17–2.85 |  | 3.54 | 1.79–7.00 |  |
 | >100,000 |  |  |  |  |  |  |  |  |
Weight (kg) (n = 77 missing) | <= 50 | 54 | 22 (41) | 1 | - | 0.02 | Â | Â | Â |
 | 51–60 | 285 | 90 (32) | 0.67 | 0.37–1.22 |  |  |  |  |
 | 61–70 | 349 | 83 (24) | 0.45 | 0.25–0.82 | Pt = 0.007 |  |  |  |
 | >70 | 185 | 46 (25) | 0.48 | 0.25–0.91 |  |  |  |  |
ART regimen | COM/EFV | 897 | 249 (28) | 1 | - | 0.04 | Â | Â | Â |
 | other | 56 | 23 (41) | 1.81 | 1.04–3.15 |  |  |  |  |
<1 log decrease in viral load at six weeks (n = 198 missing) | No | 669 | 157 (23) | 1 | - | <0.001 | 1 | Â | <0.001 |
 | Yes | 86 | 40 (47) | 2.84 | 1.79–4.49 |  | 4.71 | 2.56–8.68 |  |
Self-reported adherence at 6 weeks (n = 73 missing) | 100% | 784 | 204 (26) | 1 | - | <0.001 | 1 | Â | <0.001 |
 | <100% | 95 | 43 (45) | 2.35 | 1.52–3.63 |  | 3.50 | 1.92–6.35 |  |